You are here
Articles
Posted on Friday, November 25, 2011 - 11:48am
Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features
Posted on Monday, November 21, 2011 - 9:17pm
Posted on Wednesday, November 16, 2011 - 9:15pm
Posted on Wednesday, November 16, 2011 - 1:51pm
Apparently the link I posted seems to have a problem. This article is free so I have posted the link below. You just need to click on the button which say access this article for free and it should take you to the...
Posted on Tuesday, November 15, 2011 - 11:52am
Press release: 25th September 2011. Vaxil BioTherapeutics Ltd. a clinical-stage vaccine development company announced today that it has submitted a patent application to the United States Patent Office...
Posted on Sunday, November 13, 2011 - 7:06pm
Leukemia , (11 November 2011) | doi:10.1038/leu.2011.323
Posted on Friday, November 11, 2011 - 1:22pm
Variant Philadelphia (Ph) chromosome translocations have been reported in 5%-10% of patients with newly diagnosed chronic myeloid leukemia (CML). Variant translocations may involve one or more chromosomes in addition to...
Posted on Friday, November 11, 2011 - 1:14pm
STIM Study Examines Sustainability of Complete Molecular Response After Stopping Imatinib in CML
Elsevier Global Medical News. 2010 Jan 13, P Wendling
Posted on Thursday, November 3, 2011 - 11:23am
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised...
Posted on Saturday, September 24, 2011 - 8:23pm
Posted on Tuesday, September 6, 2011 - 2:17pm
UK CML Patient Day- Conference Agenda
http://www.mpdmeetings.org/patient-conference.aspx
Posted on Wednesday, August 24, 2011 - 1:49pm
A pivotal Phase 2 clinical trial of ARIAD’s investigational pan-BCR-ABL inhibitor, ponatinib (previously known as AP24534), is ongoing in patients with resistant or intolerant chronic myeloid leukemia...
Posted on Saturday, August 6, 2011 - 3:09pm
This is a really interesting interview with Hagop Kantarjian of MDACC, Houston where he talks about the current therapies for CML. He has an interesting view on 2nd generation TKI in front line treatment and how that...
- ‹ previous
- 17 of 29
- next ›